(Q34196628)

31 July 2017

1 reference

title

Statins and myocardial remodelling: cell and molecular pathways (English)

1 reference

31 July 2017

Neil A Turner

2

0 references

Karen E Porter

series ordinal

1

object named as

Karen E Porter

0 references

publication date

1 July 2011

1 reference

Expert Reviews in Molecular Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

13

1 reference

31 July 2017

page(s)

e22

1 reference

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Applications for ROCK kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Selenoprotein synthesis and side-effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Adverse effects of statins - mechanisms and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Toward immunomodulatory and anti-inflammatory properties of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Structural mechanism for statin inhibition of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Lovastatin inhibits TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rac inhibition reverses the phenotype of fibrotic fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Effect of pravastatin on phenotypical transformation of fibroblasts and hypertrophy of cardiomyocytes in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Infarct scar: a dynamic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Origins of cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The origin of fibroblasts and mechanism of cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Cell patterning: interaction of cardiac myocytes and fibroblasts in three-dimensional culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Cardiac fibroblast: the renaissance cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statin therapy in the prevention and treatment of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Effects of atorvastatin and simvastatin on atrial plateau currents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Molecular remodeling in the failing human heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3beta and transcription factor beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Programmed death as a therapeutic target to reduce myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Cell death in the pathogenesis of heart disease: mechanisms and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Critical role for FoxO3a-dependent regulation of p21CIP1/WAF1 in response to statin signaling in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Regulation of NADPH oxidases: the role of Rac proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Impact of HMG CoA reductase inhibition on small GTPases in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statins and the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Mechanisms and models in heart failure: the biomechanical model and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Structural and functional coupling of cardiac myocytes and fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Cardiac cellular heterogeneity and remodelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Dynamic interactions between myocytes, fibroblasts, and extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Structural and functional characterisation of cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The cardiac fibroblast: therapeutic target in myocardial remodeling and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Pleiotropic effects of statins. - Basic research and clinical perspectives -.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Cardiac fibroblasts: at the heart of myocardial remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Requirement of Rac1 in the development of cardiac hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Signaling pathways for cardiac hypertrophy and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Small guanine nucleotide-binding proteins and myocardial hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Small GTP-binding proteins and their regulators in cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Rho GTPases and signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Isoprenoids as mediators of the biological effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The role of statins in the prevention of heart failure after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Statins and mortality among elderly patients hospitalized with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Should a statin be prescribed to every patient with heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The Rac and Rho hall of fame: a decade of hypertrophic signaling hits

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Diabetes and cardiovascular risk factors: the Framingham study

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Role of Rac1 GTPase activation in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Beneficial cardiovascular pleiotropic effects of statins

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Alpha 1-adrenergic receptor coupling with Gh in the failing human heart

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1017%2FS1462399411001931

7 January 2021

10.1017/S1462399411001931

Identifiers

DOI

1 reference

31 July 2017

1 reference